Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0–1 non-small cell lung cancer: the INCREASE trial

Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0–1 non-small cell lung cancer: the INCREASE trial

Abstract Background The likelihood of a tumor recurrence in patients with T3-4N0–1 non-small cell lung cancer following multimodality treatment remains substantial, mainly due distant metastases. As pathological complete responses (pCR) in resected specimens are seen in only a minority (28–38%) of p...

Full description

Bibliographic Details
Main Authors: Chris Dickhoff, Suresh Senan, Famke L. Schneiders, Joris Veltman, Sayed Hashemi, Johannes M. A. Daniels, Marieke Fransen, David J. Heineman, Teodora Radonic, Peter M. van de Ven, Imke H. Bartelink, Lilian J. Meijboom, Juan J. Garcia-Vallejo, Daniela E. Oprea-Lager, Tanja D. de Gruijl, Idris Bahce
Format: Article
Language:English
Published: BMC 2020-08-01
Series:BMC Cancer
Subjects:
NSCLC
Neoadjuvant immunotherapy
Thoracic surgery
Locally advanced
Pathological response
Online Access:http://link.springer.com/article/10.1186/s12885-020-07263-9

Internet

http://link.springer.com/article/10.1186/s12885-020-07263-9

Similar Items